- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Erschienen in
-
In: Clinical Chemistry and Laboratory Medicine, Band 31.1993, Ausgabe 4, Seite 221-224
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Humboldt-Universität zu Berlin
- (wann)
-
2010
- Urheber
-
Gerding, H.
Cremer-Bartels, G.
Krause, K.
Busse, H.
- DOI
-
10.18452/9636
- URN
-
urn:nbn:de:kobv:11-100115019
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:48 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gerding, H.
- Cremer-Bartels, G.
- Krause, K.
- Busse, H.
- Humboldt-Universität zu Berlin
Entstanden
- 2010
Ähnliche Objekte (12)
Prognostic factors and medical treatments of patients with melanoma
Multivariate analysis of prognostic factors in patients with nodular melanoma
Phenotypes and Genotypes of Melanoma Patients
Determinants of survival in patients with brain metastases from cutaneous melanoma
Functional immunological parameters associated with long-term survival of patients with metastatic melanoma
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : : Melanoma brain metastases prognostic score
Intratumor Heterogeneity Correlates with Reduced Immune Activity and Worse Survival in Melanoma Patients
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Prognostic factors and medical treatments of patients with melanoma
Multivariate analysis of prognostic factors in patients with nodular melanoma
Phenotypes and Genotypes of Melanoma Patients
Determinants of survival in patients with brain metastases from cutaneous melanoma
Functional immunological parameters associated with long-term survival of patients with metastatic melanoma
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : : Melanoma brain metastases prognostic score
Intratumor Heterogeneity Correlates with Reduced Immune Activity and Worse Survival in Melanoma Patients
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Prognostic factors and medical treatments of patients with melanoma
Multivariate analysis of prognostic factors in patients with nodular melanoma
Phenotypes and Genotypes of Melanoma Patients
Determinants of survival in patients with brain metastases from cutaneous melanoma
Functional immunological parameters associated with long-term survival of patients with metastatic melanoma
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma
Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : : Melanoma brain metastases prognostic score
Intratumor Heterogeneity Correlates with Reduced Immune Activity and Worse Survival in Melanoma Patients
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients
The impact of brain involvement in metastatic melanoma patients treated with Pembrolizumab [Abstract]